CL2013002085A1 - Combinacion de compuestos para su uso en un procedimiento para prevenir o reducir el aumento de peso, estimular la perdida de peso, mejorar los niveles de glucosa en circulación, la tolerancia a la glucosa o los niveles de colesterol en circulacion. - Google Patents

Combinacion de compuestos para su uso en un procedimiento para prevenir o reducir el aumento de peso, estimular la perdida de peso, mejorar los niveles de glucosa en circulación, la tolerancia a la glucosa o los niveles de colesterol en circulacion.

Info

Publication number
CL2013002085A1
CL2013002085A1 CL2013002085A CL2013002085A CL2013002085A1 CL 2013002085 A1 CL2013002085 A1 CL 2013002085A1 CL 2013002085 A CL2013002085 A CL 2013002085A CL 2013002085 A CL2013002085 A CL 2013002085A CL 2013002085 A1 CL2013002085 A1 CL 2013002085A1
Authority
CL
Chile
Prior art keywords
circulating
levels
glucose
compounds
procedure
Prior art date
Application number
CL2013002085A
Other languages
English (en)
Inventor
Keld Fosgerau
Ditte Riber
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45607302&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013002085(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Publication of CL2013002085A1 publication Critical patent/CL2013002085A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CL2013002085A 2011-01-20 2013-07-19 Combinacion de compuestos para su uso en un procedimiento para prevenir o reducir el aumento de peso, estimular la perdida de peso, mejorar los niveles de glucosa en circulación, la tolerancia a la glucosa o los niveles de colesterol en circulacion. CL2013002085A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161434698P 2011-01-20 2011-01-20

Publications (1)

Publication Number Publication Date
CL2013002085A1 true CL2013002085A1 (es) 2013-12-06

Family

ID=45607302

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013002085A CL2013002085A1 (es) 2011-01-20 2013-07-19 Combinacion de compuestos para su uso en un procedimiento para prevenir o reducir el aumento de peso, estimular la perdida de peso, mejorar los niveles de glucosa en circulación, la tolerancia a la glucosa o los niveles de colesterol en circulacion.

Country Status (20)

Country Link
US (2) US20140011733A1 (es)
EP (1) EP2665487A1 (es)
JP (1) JP2014504597A (es)
KR (1) KR20140043709A (es)
CN (1) CN103491975B (es)
AR (1) AR085086A1 (es)
AU (1) AU2012208349A1 (es)
BR (1) BR112013018269A2 (es)
CA (1) CA2824397A1 (es)
CL (1) CL2013002085A1 (es)
CO (1) CO6761400A2 (es)
EA (1) EA201390796A1 (es)
MA (1) MA34913B1 (es)
MX (1) MX2013008005A (es)
PE (1) PE20140969A1 (es)
SG (1) SG192038A1 (es)
TN (1) TN2013000251A1 (es)
TW (1) TW201247702A (es)
UY (1) UY33872A (es)
WO (1) WO2012098462A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0823379A2 (pt) 2008-12-15 2015-07-14 Zealand Pharma As Análogos de glucagon
EA020596B1 (ru) 2008-12-15 2014-12-30 Зилэнд Фарма А/С Аналоги глюкагона
MX2011006314A (es) 2008-12-15 2011-09-22 Zealand Pharma As Analogos de glucagon.
AU2008365555B2 (en) 2008-12-15 2016-01-14 Zealand Pharma A/S Glucagon analogues
JP6054742B2 (ja) 2009-07-13 2016-12-27 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
AU2011269430A1 (en) 2010-06-24 2013-01-10 Zealand Pharma A/S Glucagon analogues
BR112014006684A2 (pt) 2011-09-23 2017-03-28 Novo Nordisk As análogos de glucagon
CA2872314C (en) 2012-05-03 2021-08-31 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
MY170671A (en) 2012-07-23 2019-08-26 Zealand Pharma As Glucagon analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
JP6538645B2 (ja) * 2013-03-14 2019-07-03 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン‐インクレチン複合物
BR112015025464A2 (pt) 2013-04-18 2017-10-10 Novo Nordisk As coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
HUE039616T2 (hu) 2013-10-17 2019-01-28 Zealand Pharma As Acilezett glükagon analógok
US9988429B2 (en) * 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
AU2014345569B2 (en) 2013-11-06 2020-08-13 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
BR112016009995B1 (pt) 2013-11-06 2023-04-18 Zealand Pharma A/S Compostos agonistas triplos glucagon-glp-1-gip
AR098616A1 (es) 2013-12-18 2016-06-01 Lilly Co Eli Péptido para el tratamiento de hipoglicemia severa
MA43289B1 (fr) 2014-01-20 2019-12-31 Hanmi Pharm Ind Co Ltd Insuline à action prolongée et utilisation associée
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
CN108271356A (zh) 2014-09-24 2018-07-10 印第安纳大学研究及科技有限公司 肠降血糖素-胰岛素缀合物
CA2965732A1 (en) 2014-10-29 2016-05-06 Zealand Pharma A/S Gip agonist compounds and methods
KR20170137198A (ko) 2015-04-16 2017-12-12 질랜드 파마 에이/에스 아실화된 글루카곤 유사체
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
BR102015031283A2 (pt) * 2015-12-14 2018-09-18 Univ Rio De Janeiro Bioconjugado de amilina humana ou de análogos de amilinanão agregantes, composição, métodos para a preparação deuma composição, para o tratamento de uma doença oucondição e para estabilizar um composto amilino-mimético, e,medicamento
WO2017160669A1 (en) * 2016-03-18 2017-09-21 Merck Sharp & Dohme Corp. Insulin-incretin conjugates
US11058775B2 (en) 2016-04-26 2021-07-13 Merck Sharp & Dohme Corp. Insulin dimer-incretin conjugates
WO2018056764A1 (ko) 2016-09-23 2018-03-29 한미약품 주식회사 인슐린 수용체와의 결합력이 감소된, 인슐린 아날로그 및 이의 용도
TWI798209B (zh) 2017-03-23 2023-04-11 南韓商韓美藥品股份有限公司 對胰島素受體有降低親和性之胰島素類似物之接合物及其用途
EP3900734A4 (en) * 2018-12-21 2022-10-12 Hanmi Pharm. Co., Ltd. PHARMACEUTICAL COMPOSITION WITH INSULIN AND GLUCAGON
CA3186427A1 (en) * 2020-06-11 2021-12-16 Abvance Therapeutics Inc. Systems, devices, compositions and methods for treating diabetes
WO2023088140A1 (zh) * 2021-11-19 2023-05-25 南京明德新药研发有限公司 订合肽及其应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
AU682061B2 (en) 1993-09-17 1997-09-18 Novo Nordisk A/S Acylated insulin
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
UA72181C2 (uk) 1996-08-30 2005-02-15 Ново Нордіск А/С Похідна глюкагоноподібного пептиду-1 (варіанти), фармацевтична композиція та спосіб одержання лікувального засобу (варіанти), спосіб лікування діабету (варіанти) і ожиріння
CZ295838B6 (cs) 1996-09-09 2005-11-16 Zealand Pharma A/S Způsob výroby peptidů
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
IL144989A0 (en) 1999-03-17 2002-06-30 Novo Nordisk As Method for acylating peptides and novel acylating agents
WO2003053460A1 (en) 2001-12-19 2003-07-03 Eli Lilly And Company Crystalline compositions for controlling blood glucose
BR0215029A (pt) 2001-12-20 2005-12-20 Lilly Co Eli Molécula de insulina, uso da mesma, composição, uso desta, microcristal, processo para prepará-lo, uso deste, e, métodos para preparar uma molécula de insulina, para tratar hiperglicemia, e para tratar diabetes mellitus
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
AU2004234345A1 (en) 2003-04-29 2004-11-11 Eli Lilly And Company Insulin analogs having protracted time action
KR101349808B1 (ko) 2005-06-13 2014-02-13 임페리얼 이노베이션스 리미티드 섭취행동에 관한 신규 화합물들 및 이들의 효능
WO2007081824A2 (en) 2006-01-06 2007-07-19 Case Western Reserve University Fibrillation resistant proteins
CN101389648B (zh) 2006-02-22 2013-07-17 默沙东公司 肽胃泌酸调节素衍生物
WO2008043033A2 (en) 2006-10-04 2008-04-10 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
EP2111414B1 (en) 2007-02-15 2014-07-02 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
DK2158214T3 (da) 2007-06-15 2011-12-05 Zealand Pharma As Glukagonanaloger
ES2632504T3 (es) 2007-11-20 2017-09-13 Ambrx, Inc. Polipéptidos de insulina modificados y sus usos
BRPI0907371A2 (pt) 2008-01-09 2015-11-24 Sanofi Aventis Deutschland derivados de insulina com um perfil de tempo-ação muito retardado
JP5695909B2 (ja) 2008-01-09 2015-04-08 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 極度に遅延した時間作用プロファイルを有する新規なインスリン誘導体
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
WO2009129250A2 (en) 2008-04-14 2009-10-22 Case Western Reserve University Meal-time insulin analogues of enhanced stability
MX2010011329A (es) 2008-04-22 2011-03-15 Univ Case Western Reserve Analogos de insulina especificos de isoforma.
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
MX2010012695A (es) 2008-06-17 2011-03-15 Univ Indiana Res & Tech Corp Analogos de glucagon que exhiben solubilidad y estabilidad aumentadas en soluciones reguladoras de ph fisiologico.
PA8830501A1 (es) * 2008-06-17 2010-07-27 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
PL219335B1 (pl) 2008-07-04 2015-04-30 Inst Biotechnologii I Antybiotyków Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
CN102171245B (zh) 2008-07-31 2015-03-25 卡斯西部储备大学 卤素稳定型胰岛素
BRPI0823379A2 (pt) * 2008-12-15 2015-07-14 Zealand Pharma As Análogos de glucagon
AU2008365555B2 (en) * 2008-12-15 2016-01-14 Zealand Pharma A/S Glucagon analogues
MX2011006314A (es) * 2008-12-15 2011-09-22 Zealand Pharma As Analogos de glucagon.
EA020596B1 (ru) * 2008-12-15 2014-12-30 Зилэнд Фарма А/С Аналоги глюкагона
CN102256992B (zh) 2008-12-19 2015-04-22 印第安纳大学研究及科技有限公司 胰岛素类似物
JP5755566B2 (ja) 2008-12-19 2015-07-29 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ アミド系インスリンプロドラッグ
CN101519446A (zh) 2009-03-31 2009-09-02 上海一就生物医药有限公司 一种重组人胰岛素及其类似物的制备方法
JP6054742B2 (ja) * 2009-07-13 2016-12-27 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体
NZ603169A (en) * 2010-04-27 2015-02-27 Zealand Pharma As Peptide conjugates of glp-1 receptor agonists and gastrin and their use
AR081975A1 (es) * 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon

Also Published As

Publication number Publication date
WO2012098462A1 (en) 2012-07-26
CN103491975B (zh) 2016-05-11
UY33872A (es) 2012-08-31
CO6761400A2 (es) 2013-09-30
AU2012208349A1 (en) 2013-07-18
US20140011733A1 (en) 2014-01-09
AR085086A1 (es) 2013-09-11
JP2014504597A (ja) 2014-02-24
KR20140043709A (ko) 2014-04-10
SG192038A1 (en) 2013-08-30
EP2665487A1 (en) 2013-11-27
MX2013008005A (es) 2013-08-21
US20160000883A1 (en) 2016-01-07
CA2824397A1 (en) 2012-07-26
EA201390796A1 (ru) 2014-07-30
NZ612719A (en) 2015-05-29
TW201247702A (en) 2012-12-01
CN103491975A (zh) 2014-01-01
BR112013018269A2 (pt) 2017-06-06
TN2013000251A1 (en) 2014-11-10
PE20140969A1 (es) 2014-07-24
MA34913B1 (fr) 2014-02-01

Similar Documents

Publication Publication Date Title
CL2013002085A1 (es) Combinacion de compuestos para su uso en un procedimiento para prevenir o reducir el aumento de peso, estimular la perdida de peso, mejorar los niveles de glucosa en circulación, la tolerancia a la glucosa o los niveles de colesterol en circulacion.
CL2013003129A1 (es) Composicion herbicida de emulsión de aceite en agua, estable de alta resistencia; metodo para preparar dicha composicion.
SMT201600155B (it) Pirazolo[i, 5-a]pirimidine e -triazine come agenti antivirali
CO6930363A2 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
BR112014015535A2 (pt) uso de compostos de fórmula i, método para combater fungos fitopatogênicos e composições agroquímicas
DK2661243T3 (da) Konstruktioner, opnåede ved vævsteknologi
CO6970598A2 (es) Derivados de 4-pregenen-11ss-17-21-triol-3,20-diona para el tratamiento de afecciones oculares
ES2969625T3 (es) Procedimientos para tratar el aumento de peso inducido por antipsicóticos
BR112014013213A2 (pt) composição microbicida, método para fornecer um efeito bactericida a um substrato e uso de uma composição
CL2014003565A1 (es) Uso de 2-metileno-19-nor-(20s)-1alpha,25-dihidroxivitamina d3 para tratar el hiperparatiroidismo secundario.
BR112013020608A2 (pt) simulador para formação de equipe, particularmente, para formação de tripulação de helicóptero
CL2013003487A1 (es) Uso de un compuesto derivado de fosforamidato de nucleosido para tratar la fiebre dengue y compuestos especificos.
CL2013002823A1 (es) Compuestos derivados de morfolinotieno[3,2-d]pirimidin-6-il-metil-(metilamino)-n-hidroxipirimidina-5-carboxamida, inhibidores de la pi3 quinasa; composicion farmaceutica que los comprende; su uso en el tratamiento de un trastorno de proliferacion celular tal como el cancer.
BR112014002830A2 (pt) fotossensibilizador para uso terapêutico
AR089320A1 (es) Cepa de lactobacillus mucosae
CL2014002345A1 (es) Uso de tralopiril contra barrenadores de la madera marinos
ES2388864B1 (es) Procedimiento de estabilizacion de fosfoyesos para la disminucion de las emisiones de radionucleidos naturales.
BRPI0914636A2 (pt) diaril ureias para tratar insuficiência cardíaca
BR112013010274A2 (pt) composição de emulsão para uso como potencializador em uma formulação herbicida líquida solúvel, método para preparar uma composição de emulsão, formulação herbicida líquida solúvel, método para melhorar o desempenho da formulação herbicida líquida solúvel e uso de uma composição de emulsão
BR112013016244A2 (pt) microvesículas cheias de gás para uso como vacinas.
CR20150160A (es) Derivados de macrólidos, su preparación y su uso terapéutico
CO6880061A2 (es) Método para tratar el cáncer mediante el uso combinado de fármacos
BRPI1016081A2 (pt) composição e método e composto para tratar degeneração macular, bem como uso de um composto 15-ceto prostaglandina
CO7071125A2 (es) Composiciones, síntesis y métodos para el uso de derivados de fenilcicloalquilmetilamino
ES1075233Y (es) Soporte para laminados fotovoltaicos